Japan Approves Rheumatoid Drug Baricitinib for Covid-19 Patients
Japan’s health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone. Eli Lilly & Co’s